PURPOSE: We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET. METHODS AND MATERIALS: 8 patients with GEP-NET were imaged using CE-MRI (Gd-EOB-DTPA), CE-CT (Imeron 400) and DOTATOC-PET. Contrast-enhancement of normal liver-tissue and metastasis was quantified with ROI-technique. Tumor delineation was assessed with visual-score in blind-read-analysis by two experienced radiologists. RESULTS: Out of 40 liver metastases in patients with NETs, all were detected by CE-MRI and the lesion extent could be adequately assessed, whereas CT failed to detect 20% of all metastases. The blind-read-score of CT in arterial and portal phase was median -0.65 and -1.4, respectively, and 2.7 for delayed-MRI. The quantitative ROI-analysis presented an improved contrast-enhancement-ratio with a median of 1.2, 1.6 and 3.3 for CE-CT arterial, portal-phase and delayed-MRI respectively. CONCLUSION: Late CE-MRI was superior to CE-CT in providing additionally morphologic characterization and exact lesion extension of hepatic metastases from neuroendocrine tumor detected with DOTATOC-PET. Therefore, late enhanced Gd-EOB-DTPA-MRI seems to be the adequate imaging modality for combination with DOTATOC-PET to provide complementary (macroscopic and molecular) tumor characterization in hepatic metastasized NETs.
RCT Entities:
PURPOSE: We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET. METHODS AND MATERIALS: 8 patients with GEP-NET were imaged using CE-MRI (Gd-EOB-DTPA), CE-CT (Imeron 400) and DOTATOC-PET. Contrast-enhancement of normal liver-tissue and metastasis was quantified with ROI-technique. Tumor delineation was assessed with visual-score in blind-read-analysis by two experienced radiologists. RESULTS: Out of 40 liver metastases in patients with NETs, all were detected by CE-MRI and the lesion extent could be adequately assessed, whereas CT failed to detect 20% of all metastases. The blind-read-score of CT in arterial and portal phase was median -0.65 and -1.4, respectively, and 2.7 for delayed-MRI. The quantitative ROI-analysis presented an improved contrast-enhancement-ratio with a median of 1.2, 1.6 and 3.3 for CE-CT arterial, portal-phase and delayed-MRI respectively. CONCLUSION: Late CE-MRI was superior to CE-CT in providing additionally morphologic characterization and exact lesion extension of hepatic metastases from neuroendocrine tumor detected with DOTATOC-PET. Therefore, late enhanced Gd-EOB-DTPA-MRI seems to be the adequate imaging modality for combination with DOTATOC-PET to provide complementary (macroscopic and molecular) tumor characterization in hepatic metastasized NETs.
Authors: C Kratochwil; M Stefanova; E Mavriopoulou; T Holland-Letz; A Dimitrakopoulou-Strauss; A Afshar-Oromieh; W Mier; U Haberkorn; F L Giesel Journal: Mol Imaging Biol Date: 2015-06 Impact factor: 3.488
Authors: Paul Flechsig; Christina Walker; Clemens Kratochwil; Laila König; Andrei Iagura; Jan Moltz; Tim Holland-Letz; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel Journal: Mol Imaging Biol Date: 2018-08 Impact factor: 3.488
Authors: Matthaeus Cieciera; Clemens Kratochwil; Jan Moltz; Hans Ulrich Kauczor; Tim Holland Letz; Peter Choyke; Walter Mier; Uwe Haberkorn; Frederik L Giesel Journal: Diagn Interv Radiol Date: 2016 May-Jun Impact factor: 2.630
Authors: Sarah Wulfert; Clemens Kratochwil; Peter L Choyke; Ali Afshar-Oromieh; Walter Mier; Hans-Ulrich Kauczor; Jens-Peter Schenk; Uwe Haberkorn; Frederik L Giesel Journal: Mol Imaging Biol Date: 2014-08 Impact factor: 3.488
Authors: Marius E Mayerhoefer; Ahmed Ba-Ssalamah; Michael Weber; Markus Mitterhauser; Harald Eidherr; Wolfgang Wadsak; Markus Raderer; Siegfried Trattnig; Andreas Herneth; Georgios Karanikas Journal: Eur Radiol Date: 2013-03-08 Impact factor: 5.315
Authors: Christine Schmid-Tannwald; Christoph M Schmid-Tannwald; John N Morelli; Ralph Neumann; Alexander R Haug; Nathalie Jansen; Konstantin Nikolaou; Nicolai Schramm; Maximilian F Reiser; Carsten Rist Journal: Eur J Nucl Med Mol Imaging Date: 2013-03-05 Impact factor: 9.236
Authors: Stephen A Deppen; Eric Liu; Jeffrey D Blume; Jeffrey Clanton; Chanjuan Shi; Laurie B Jones-Jackson; Vipul Lakhani; Richard P Baum; Jordan Berlin; Gary T Smith; Michael Graham; Martin P Sandler; Dominique Delbeke; Ronald C Walker Journal: J Nucl Med Date: 2016-01-14 Impact factor: 10.057